Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group

Neuro Oncol. 2019 Jan 1;21(1):26-36. doi: 10.1093/neuonc/noy137.


No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials as Topic*
  • Combined Modality Therapy
  • Disease Progression
  • Humans
  • Meningeal Neoplasms / diagnostic imaging
  • Meningeal Neoplasms / pathology*
  • Meningeal Neoplasms / therapy
  • Meningioma / diagnostic imaging
  • Meningioma / pathology*
  • Meningioma / therapy
  • Neuroimaging / methods*
  • Outcome and Process Assessment, Health Care*
  • Practice Guidelines as Topic / standards*